Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Beckley Psytech
One of the best-attended sessions at the BIO meeting in San Diego saw psychedelics specialists weighing up the sector's chances of breaking taboos and getting to market.
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.
Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.
- Drug Delivery